Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021–2023

• Published in: Vaccine p. 125827
• Main Authors: Dahl, Benjamin A., Tritter, Beth, Butryn, Deena, Dahlke, Melissa, Browning, Sean, Gelting, Richard, Fleming, Monica, Ortiz, Nancy, Labrador, Jacqueline, Novak, Ryan, Fitter, David, Bell, Elizabeth, McGuire, Megan, Rosenbaum, Robert, Pulwer, Robert, Wun, Jolene, McCaffrey, Anna, Chowdhury, Maisoon, Parks, Nida, Cunningham, Marc, Mounts, Anthony, Curry, Dora, Richardson, Dominique, Grant, Gavin
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 23-03-2024
• Subjects: Coronavirus disease; COVID-19; Evaluation; Global Vax; Implementation; SARS-CoV-2; Vaccine; Vaccine delivery; COVID-19; Evaluation; SARS-CoV-2; Coronavirus disease; Vaccine; Global Vax; Vaccine delivery; Implementation
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2024.03.054

In December 2021 the U.S. Government announced a new, whole-of-government $1.8 billion effort, the Initiative for Global Vaccine Access (Global VAX) in response to the global COVID-19 pandemic. Using the foundation of decades of U.S. government investments in global health and working in close partnership with local governments and key global and multilateral organizations, Global VAX enabled the rapid acceleration of the global COVID-19 vaccine rollout in selected countries, contributing to increased COVID-19 vaccine coverage in some of the world’s most vulnerable communities. Through Global VAX, the U.S. Government has supported 125 countries to scale up COVID-19 vaccine delivery and administration while strengthening primary health care systems to respond to future health crises. The progress made by Global VAX has paved the way for a stronger global recovery and improved global health security.